The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "psoriasis"

Search results for: psoriasis

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

August 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: mirikizumab, plaque psoriasis, secukinumab

Study Finds Increased Risk of Cancer in Psoriasis Patients

August 5, 2020 • By Lara C. Pullen, PhD

Recent research reinforces the finding that psoriasis patients have a slightly increased risk of cancer, specifically keratinocyte cancer and lymphomas. However, the study found no association between cancer and the use of biologic treatments in this patient population…... [Read More]

Filed Under: Conditions Tagged With: Cancer, cancer risk, Psoriasis

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

August 4, 2020 • By Michele B. Kaufman, PharmD, BCGP

In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: ixekizumab, nail psoriasis, Psoriasis, ustekinumab

Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis

July 14, 2020 • By Michele B. Kaufman, PharmD, BCGP

Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: genital psoriasis, ixekizumab, Psoriasis, sexual health

Apremilast Promising for Plaque Psoriasis

July 6, 2020 • By Michele B. Kaufman, PharmD, BCGP

Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…... [Read More]

Filed Under: Analgesics, Drug Updates Tagged With: apremilast, plaque psoriasis, skin

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

February 5, 2020 • By Michele B. Kaufman, PharmD, BCGP

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: plaque psoriasis, risankizumab, secukinumab

Tildrakizumab Promising for Psoriasis in Patients with PsA

December 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: 2019 ACR/ARP Annual Meeting, Psoriasis, psoriatic arthritis, tildrakizumab

Rheumatology Drugs at a Glance, Part 2: Psoriasis

May 17, 2019 • By Mary Choy, PharmD, BCGP, FASHP

MicroOne / shutterstock.com

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to… [Read More]

Filed Under: Conditions, Drug Updates Tagged With: adalimumab, apremilast, brodalumab, Certolizumab Pegol, etanercept, guselkumab, guttate psoriasis, infliximab, inverse psoriasis, ixekizumab, psoriatic erythroderma, pustular psoriasis, Rheumatic Drugs at a Glance, secukinumab, tildrakizumab, ustekinumab, vulgar psoriasis

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

May 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…... [Read More]

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: Canada, FDA, meloxicam, non-opioid pain shot, Pain, plaque psoriasis, rizankixumab, U.S. Food and Drug Administration (FDA)

Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

April 15, 2019 • By Michele B. Kaufman, PharmD, BCGP

Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Japan, Psoriasis, psoriatic arthritis, risankizumab

  • 1
  • 2
  • 3
  • …
  • 43
  • Next Page »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.